More From This Series:
Part 1: RX Review: RSV Prevention Strategies and the Changing Epidemiologic Landscape
Part 3: RX Review: Evolving RSV Strategies Call for Multispecialty Collaboration
RX Review: The Evolving Landscape of RSV Prevention in Pediatrics and Beyond - Episode null
RX Review: Clesrovimab, RSV Education, and Immunization Uptake
Published on:
In this video, part 2 in a 3-part series, panelists discuss clesrovimab's recent approval and gaps in clinician education.
In this special report from HCP Live and Contemporary Pediatrics RX Review, Albert Rizzo, MD, moderates a discussion with Tina Tan, MD, and Joanne Nazif, MD, to address critical unmet needs and recent FDA approvals that are shaping pediatric respiratory syncytial virus (RSV) management.
In this clip, Tan highlights initial shortages of nirsevimab, a monoclonal antibody, as a key barrier to broad immunoprophylaxis. Although supply has since improved, she underscores ongoing challenges in ensuring widespread, timely access, especially amid shifting RSV seasonality post-pandemic.
Nazif discusses the recent FDA approval of clesrovimab, a new RSV monoclonal antibody for infants, which joins maternal vaccination and nirsevimab as prevention options. She notes its fixed-dose delivery simplifies administration and offers supply resilience and potential protection against viral mutations by targeting RSV differently. Clesrovimab (Merck) was approved by the FDA last month under the name Enflonsia.
Both experts emphasize gaps in clinician education. Tan stresses the importance of understanding appropriate use of maternal and infant-targeted RSV prevention tools. Nazif addresses the importance of parental communication amid vaccine hesitancy, urging providers to differentiate monoclonal antibodies from traditional vaccines and to reinforce the rigorous safety evaluations these products undergo.
Our Panelists:
Albert Rizzo, MD, is chief medical officer of the American Lung Association. Board certified in internal medicine, pulmonary, critical care and sleep medicine, Rizzo serves as the moderator for this panel discussion.
Tina Tan, MD, is a professor of pediatrics at the Feinberg School of Medicine at Northwestern University and an infectious disease physician. She is also medical director of the International Patient and Destination Services Program, president of the Lurie medical dental staff at Ann & Robert H. Lurie Children’s Hospital of Chicago, and president of the Infectious Disease Society of America.
Joanne Nazif, MD, is an attending physician in the division of Hospital Medicine at Children's Hospital at Montefiore. She also serves as an associate professor of pediatrics at Albert Einstein College of Medicine.
Rizzo, Tan, and Nazif report no relevant disclosures.
